Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 5/20 | 0.61 |
| ▸ | ESR2 | Q92731 | 5/20 | 0.61 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | ABHD6 | Q9BV23 | 10/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.41 |
| ▸ | MGLL | Q99685 | 4/20 | 0.41 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7854911 | 0.82 | ESR1 (0.70) | ESR1ESR2PKMABHD6HRH3 | |
| SCHEMBL31164691 | 0.81 | ESR1 (0.90) | ESR1ESR2PKMABHD6 | |
| SCHEMBL1367390 | 0.79 | ESR1 (0.64) | ESR1ESR2PKMABHD6 | |
| SCHEMBL8373032 | 0.77 | ESR1 (0.61) | ESR1ESR2PKMABHD6NR1H2 | |
| SCHEMBL29989790 | 0.77 | ESR1 (0.76) | ESR1ESR2PKMABHD6 | |
| SCHEMBL2821470 | 0.77 | ESR1 (0.76) | ESR1ESR2PKMABHD6 | |
| SCHEMBL8266789 | 0.77 | ESR1 (0.72) | ESR1ESR2PKMABHD6NR1H2 | |
| SCHEMBL3895230 | 0.76 | ESR1 (1.00) | ESR1ESR2ABHD6 | |
| SCHEMBL3893409 | 0.76 | ESR1 (0.75) | ESR1ESR2ABHD6MGLL | |
| SCHEMBL4183920 | 0.75 | ESR1 (0.74) | ESR1ESR2PKMABHD6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8173648-B2 | 1,2,3,4-tetrahydroisoquinoline derivatives, preparation process therefor and pharmaceutical composition containing the same | NATIONAL DEFENSE MEDICAL CENTER (TW) | 2012-05-08 | — | — | US | claimed |
| US-20100016309-A1 | 1,2,3,4-Tetrahydroisoquinoline Derivatives, Preparation Process therefor and Pharmaceutical Composition Containing the Same | NATIONAL DEFENSE MEDICAL CENTER (TW) | 2010-01-21 | — | — | US | claimed |
| US-8173648-B2 | 1,2,3,4-tetrahydroisoquinoline derivatives, preparation process therefor and pharmaceutical composition containing the same | NATIONAL DEFENSE MEDICAL CENTER (TW) | 2012-05-08 | — | — | US | disclosed |
| US-20100016309-A1 | 1,2,3,4-Tetrahydroisoquinoline Derivatives, Preparation Process therefor and Pharmaceutical Composition Containing the Same | NATIONAL DEFENSE MEDICAL CENTER (TW) | 2010-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016309-A1 | 1,2,3,4-Tetrahydroisoquinoline Derivatives, Preparation Process therefor and Pharmaceutical Composition Containing the Same | APP, BACE1, PSEN1 | ESR1 2972/4885ESR2 3287/4885PKM 1467/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.